Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Complete Title: ADVL1721, A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma
Trial Phase: I/II
Investigator: Julie Park, MD
This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.
Keywords:
- Neoplasms, Complex and Mixed
- Neoplasms, Malignant
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
Pediatric
I/II
Julie Park, MD
ADVL1721
NCT03458728
ADVL1721, A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma
Neoplasms, Complex and Mixed
Neoplasms, Malignant